Company Overview and News

12
Facebook Loses Italy’s Biggest Bank as a Friend - Bloomberg

2018-08-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CRZBY SONO FB UL UNLYF ULVR UN GOOG UNLNF SONOS CRZBF GOOGL TWTR

7
Pepsi's Nooyi Leaves Us Feeling a Bit Flat - Bloomberg

2018-08-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
WWAV BN BUD UL UNLYF ULVR UN GPDNF UNLNF DANOY PEP ABI KHC AHBIF

7
Opinion | PepsiCo CEO Indra Nooyi’s resignation leaves us feeling a bit flat

2018-08-06 livemint
Indra Nooyi will step down as chief executive officer of PepsiCo Inc., Bloomberg News reported Monday. Two big problems trail in her wake. Her departure, scheduled for October, leaves the S&P 500 on track to have just 23 female CEOs, less than 5% of the total, according to data from Catalyst, a non-profit research and advisory group.
WWAV BN BUD UL UNLYF ULVR UN GPDNF UNLNF DANOY PEP ABI KHC AHBIF

116
Tracking Yacktman Asset Management Portfolio - Q2 2018 Update

2018-08-06 seekingalpha - 2
Yacktman Asset Management decreased Twenty-First Century Fox, Microsoft, Sysco, and Cisco Systems substantially during the quarter.
ATHTF SYY XOM ULVR AVP RDI CHRW UNLNF UHAL SYK CSCO CMCSK ABBV HSY MO CRMT FOX GLW BAC HSYFB NWS NWSA UNLYF INFY BRK.A JNJ BK INFY ABBV MSFT CLX FOXA WFCNP PG CCV CCZ BAC COP OTEL PM RDIB NWS KO ORCL DIS WFC GJV UL UN CMCSA ANTM PEP CCV.CL OCLCF ANTX

4
All the Things Satellites Can Now See From Space - Bloomberg

2018-07-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LMT BCS UL XOM UNLYF ULVR UN UNLNF 83SF 83SK RTN 47MC

 
Unilever PLC (UL) CEO Paul Polman on Q2 2018 Results - Earnings Call Transcript

2018-07-20 seekingalpha
Good morning, and welcome to Unilever's first half results. Paul and Graeme will summarize the results and the progress we have made towards our 2020 goals and then give an update on the simplification of our dual-headed legal structure. Paul will wrap up with our outlook for the year, and we'll leave plenty of time for Q&A.
UL UN UNLYF ULVR UNLNF

23
So This Is Why Trump Tweets About Oil - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
UL UNLYF CCV ULVR UN CMCSA CCZ GOOG UNLNF CCV.CL GOOGL KHC CMCSK DIS

 
Unilever Plc 2018 Q2 - Results - Earnings Call Slides

2018-07-19 seekingalpha
The following slide deck was published by Unilever Plc in conjunction with their 2018 Q2 earnings call.
UL UN UNLYF ULVR UNLNF

 
HUL Q1 results today. Here is what to expect

2018-07-16 livemint
Hindustan Unilever Ltd (HUL), India’s largest listed consumer packaged goods firm by sales, will announce its results for the June 2018 quarter today. A Bloomberg poll of 15 analysts has estimated HUL’s Q1 profit at Rs 1,540 crore and revenues at Rs 9,669 crore. This is the second quarter in a row that the India unit of Unilever Plc has witnessed high raw material inflation. Crude at $78 for a barrel remains firm.
UL UN UNLYF ULVR 500696 HINDUNILVR UNLNF

 
PRESS DIGEST- Financial Times - July 13

2018-07-13 reuters
July 13 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
BT.A UL UN UNLYF ULVR BTGOF UNLNF BT

 
P&G says 'vast majority' of products in Canada to be hit by tariffs

2018-07-12 theedgemarkets
CHICAGO (July 12): Many Procter & Gamble Co products sold in Canada — from Febreze candles to Gillette shaving foam — will be affected by retaliatory tariffs on US-made goods after Canadian authorities rejected a request for exemptions, a P&G spokesman said on Wednesday.
UL UN UNLYF ULVR UNLNF

 
P&G says 'vast majority' of products in Canada to be hit by tariffs

2018-07-12 reuters
CHICAGO (Reuters) - Many Procter & Gamble Co (PG.N) products sold in Canada - from Febreze candles to Gillette shaving foam - will be affected by retaliatory tariffs on U.S.-made goods after Canadian authorities rejected a request for exemptions, a P&G spokesman said on Wednesday.
UL UN UNLYF ULVR UNLNF

 
BASF Playing China Matchmaker Should Worry U.S. - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
STAN BNPQY ULVR OGZD UNLNF HSB STAB STAC SCBFF STAN BFFAF HSBC SYT HBCYF UL UN UNLYF BNPQF DDAIF HCS SYENF VLKAF 0005 BNPZY 580001 2888 HSEA HSEB BASFY BFA 81JK

7
Twitter Follower Numbers to Drop as It Removed Locked Accounts - WSJ

2018-07-11 wsj
Twitter Inc. TWTR 0.27% said it is subtracting some accounts it has flagged for suspicious activity from the follower numbers of its hundreds of millions of users, part of the social-media company’s efforts to clamp down on abusive activity.
UL UN UNLYF ULVR TWTR UNLNF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 904784501